Glucagon-like peptide-1 agonism - GLP-1, common in obesity medicines - is not essential to weight management, according to preclinical research led by Richard DiMarchi and Matthias Tschöp, with funding from their startup company Bluewater Biosciences.
Here’s the gov.uk page on adverse effects: https://www.gov.uk/drug-safety-update/glp-1-receptor-agonists-reminder-of-the-potential-side-effects-and-to-be-aware-of-the-potential-for-misuse
82 deaths linked to averse reactions to GLP-1 agonists, BMJ: https://www.bmj.com/content/388/bmj.r390 Unfortunately not open access.